Department of Diagnostic Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Department of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
J Cardiovasc Magn Reson. 2023 Jun 26;25(1):36. doi: 10.1186/s12968-023-00949-6.
The purpose of this meta-analysis was to comprehensively investigate the diagnostic ability of 1.5 T and 3.0 T whole heart coronary angiography (WHCA) to detect significant coronary artery disease (CAD) on X-ray coronary angiography.
A literature search of electronic databases, including PubMed, Web of Science Core Collection, Cochrane advanced search, and EMBASE, was performed to retrieve and integrate articles showing significant CAD detectability of 1.5 and 3.0 T WHCA.
Data from 1899 patients from 34 studies were included in the meta-analysis. 1.5 T WHCA had a summary area under ROC of 0.88 in the patient-based analysis, 0.90 in the vessel-based analysis, and 0.92 in the segment-based analysis. These values for 3.0 T WHCA were 0.94, 0.95, 0.96, respectively. Contrast-enhanced 3.0 T WHCA had significantly higher specificity than non-contrast-enhanced 1.5 T WHCA on a patient-based analysis (0.87, 95% CI 0.80-0.92 vs. 0.74, 95% CI 0.64-0.82, P = 0.02). There were no differences in diagnostic performance on a patient-based analysis by use of vasodilators, beta-blockers or between Asian and Western countries.
The diagnostic performance of WHCA was deemed satisfactory, with contrast-enhanced 3.0 T WHCA exhibiting higher specificity compared to non-contrast-enhanced 1.5 T WHCA in a patient-based analysis. There were no significant differences in diagnostic performance on a patient-based analysis in terms of vasodilator or beta-blocker use, nor between Asian and Western countries. However, further large-scale multicentre studies are crucial for the widespread global adoption of WHCA.
本荟萃分析的目的是全面研究 1.5T 和 3.0T 全心脏冠状动脉造影(WHCA)在 X 射线冠状动脉造影上检测显著冠状动脉疾病(CAD)的诊断能力。
通过电子数据库(包括 PubMed、Web of Science 核心合集、Cochrane 高级搜索和 EMBASE)进行文献检索,以检索并整合显示 1.5 和 3.0T WHCA 检测显著 CAD 的可探测性的文章。
来自 34 项研究的 1899 名患者的数据纳入荟萃分析。基于患者的分析中,1.5T WHCA 的汇总 ROC 曲线下面积为 0.88,基于血管的分析中为 0.90,基于节段的分析中为 0.92。3.0T WHCA 的这些值分别为 0.94、0.95、0.96。基于患者的分析中,增强对比的 3.0T WHCA 的特异性显著高于非增强对比的 1.5T WHCA(0.87,95%CI 0.80-0.92 比 0.74,95%CI 0.64-0.82,P=0.02)。在基于患者的分析中,使用血管扩张剂、β受体阻滞剂或亚洲和西方国家之间,诊断性能没有差异。
WHCA 的诊断性能被认为是令人满意的,与基于患者的分析中,增强对比的 3.0T WHCA 比非增强对比的 1.5T WHCA 具有更高的特异性。在基于患者的分析中,在使用血管扩张剂或β受体阻滞剂方面,或在亚洲和西方国家之间,诊断性能没有显著差异。然而,进一步的大规模多中心研究对于 WHCA 在全球范围内的广泛应用至关重要。